Selective, potent PPARγ agonists with cyclopentenone core structure

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 7, 2009, Pages 1883-1886

  Paz Otero, M ^a   Santín, Efrén Pérez ^a   Rodríguez Barrios, Fátima ^a   Vaz, Belén ^a   de Lera, Ángel R ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Agonists; Cyclopentenones; Nuclear receptors; PPARs; Prostaglandins

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ALKYNYL GROUP; CYCLOPENTENONE; METHANOL DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; CYCLOPENTANE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; DIASTEREOISOMER; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; REACTION ANALYSIS; THERMODYNAMICS; TRANSACTIVATION; CELL LINE; CHEMISTRY; COMPUTER SIMULATION; DRUG POTENTIATION; HELA CELL; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CELL LINE; COMPUTER SIMULATION; CYCLOPENTANES; HELA CELLS; HUMANS; PPAR GAMMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61849101947     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.072     Document Type: Article

References (73)

1. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Nature 358 (1992) 771
2. Mangelsdorf D.J., and Evans R.M. Cell 83 (1995) 841
3. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. Nature 384 (1996) 39
4. Hertz R., Berman I., Keppler D., and Bar-Tana J. Eur. J. Biochem. 235 (1996) 242
5. Spiegelman B.M. Cell 93 (1998) 153
6. Kliewer S.A., Lehmann J.M., and Willson T.M. Science 284 (1999) 757
7. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. J. Med. Chem. 43 (2000) 527
8. Kersten S., Desvergne B., and Wahli W. Nature 405 (2000) 421
9. Nencioni A., Wesselborg S., and Brossart P. Crit. Rev. Immunol. 23 (2003) 1
10. Shearer B.G., and Hoekstra W.J. Curr. Med. Chem. 10 (2003) 267
11. Rangwala S.M., and Lazar M.A. Trends Pharm. Sci. 25 (2004) 331
12. Evans R.M., Barish G.D., and Wang Y.X. Nat. Med. 10 (2004) 355
13. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5306
14. Shi Y., Hon M., and Evans R.M. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 2613
15. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15924
16. Henke B.R., Blanchard S.G., Brackeen M.F., Brown K.K., Cobb J.E., Collins J.L., Harrington Jr. W.W., Hashim M.A., Hull-Ryde E.A., Kaldor I., Kliewer S.A., Lake D.H., Leesnitzer L.M., Lehmann J.M., Lenhard J.M., Orband-Miller L.A., Miller J.F., Mook Jr. R.A., Noble S.A., Oliver Jr. W., Parks D.J., Plunket K.D., Szewczyk J.R., and Willson T.M. J. Med. Chem. 41 (1998) 5020
17. Collins J.L., Blanchard S.G., Boswell G.E., Charifson P.S., Cobb J.E., Henke B.R., Hull-Ryde E.A., Kazmierski W.M., Lake D.H., Leesnitzer L.M., Lehmann J., Lenhard J.M., Orband-Miller L.A., Gray-Nunez Y., Parks D.J., Plunkett K.D., and Tong W.Q. J. Med. Chem. 41 (1998) 5037
18. Cobb J.E., Blanchard S.G., Boswell E.G., Brown K.K., Charifson P.S., Cooper J.P., Collins J.L., Dezube M., Henke B.R., Hull-Ryde E.A., Lake D.H., Lenhard J.M., Oliver Jr. W., Oplinger J., Pentti M., Parks D.J., Plunket K.D., and Tong W.Q. J. Med. Chem. 41 (1998) 5055
19. Hiragun A., Sato M., and Mitsui H. J. Cell. Physiol. 134 (1988) 124
20. Hauner H. Diabetes/Metab. Res. Rev. 18 (2002) S10
21. Kletzien R.F., Clarke S.D., and Ulrich R.G. Mol. Pharmacol. 41 (1992) 393
22. Tugwood J.D., and Montague C.T. Human Exp. Toxicol. 21 (2002) 429
23. Pickavance L.C., Tadayyon M., Widdowson P.S., Buckingham R.E., and Wilding J.P.H. Br. J. Pharmacol. 128 (1999) 1570
24. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perrodu M., Parker M.G., and Wahli W. Mol. Endocrinol. 11 (1997) 779
25. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 4318
26. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. Cell 83 (1995) 803
27. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. Cell 83 (1995) 813
28. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., and Glass C.K. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4844
29. Straus D.S., and Glass C.K. Med. Res. Rev. 21 (2001) 185
30. Shiraki T., Kamiya N., Shiki S., Kodama T.S., Kakizuka A., and Jingami H. J. Biol. Chem. 280 (2005) 14145
31. Soares A.F., Nosjean O., Cozzone D., D'Orazio D., Becchi M., Guichardant M., Ferry G., Boutin J.A., Lagarde M., and Géloën A. Biochem. Biophys. Res. Commun. 337 (2005) 521
32. Piancatelli G., Scettri A., David G., and D'auria M. Tetrahedron 34 (1978) 2775
33. Piancatelli G., Scettri A., and Barbadoro S. Tetrahedron Lett. 17 (1976) 3555
34. Piancatelli G., and Scettri A. Synth. Commun. 7 (1977) 116
35. Piancatelli G., D'Auria M., and D'Onofrio F. Synthesis (1994) 867
36. Nieto Faza O., Silva Lopez C., Alvarez R., and de Lera A.R. Chem. Eur. J. 10 (2004) 4324
37. These 2-alkyl-4-hydroxycyclopentenones are the starting materials for the synthesis of isoprostanes, phytoprostanes and other polyunsaturated fatty acids (PUFAs). For a recent review, see:. Jahn U., Galano J.-M., and Durand T. Angew. Chem., Int. Ed. 47 (2008) 5894
38. Corey E.J., and Venkateswarlu A. J. Am. Chem. Soc. 94 (1972) 6190
39. Myers A.G., and Dragovich P.S. J. Am. Chem. Soc. 115 (1993) 7027
40. Johnson C.R., Adams J.P., Braun M.P., and Senanayake C.B.W. Tetrahedron Lett. 33 (1992) 919
41. Luche J.L., and Gemal A.L. J. Am. Chem. Soc. 101 (1979) 5848
42. Luche J.L. J. Am. Chem. Soc. 100 (1978) 2226
43. Gemal A.L., and Luche J.L. J. Am. Chem. Soc. 103 (1981) 5454
44. Johnstone R.A.W., and Rose M.E. Tetrahedron 35 (1979) 2169
45. Stewart C.A., and VanderWerp C.A. J. Am. Chem. Soc. 76 (1954) 1259
46. Corey E.J., and Schmidt G. Tetrahedron Lett. 20 (1979) 399
47. 4 dihedral (120° and 25°, respectively measured with Spartan; Wavefunction, I. V. K., Suite 370 PC Spartan, with semiempirical AM1, Irvine, CA.).
48. Hostetler E.D., Fallis S., McCarthy T., Welch M.J., and Katzenellenbogen J.A. J. Org. Chem. 63 (1998) 1348
49. Stille J.K. Angew. Chem., Int. Ed. 25 (1986) 508
50. Stille J.K. Pure Appl. Chem. 57 (1985) 1771
51. Mitchell T.N. Synthesis (1992) 803
52. Farina V., and Roth G.P. Advances in Metal-Organic Chemistry Vol. 5 (1996), JAI Press, New York
53. Farina, V.; Krishnamurthy, V.; Scott, W. J., Organic Reactions. New York, 1997; Vol. 50, Chapter 1.
54. Farina V. Pure Appl. Chem. 68 (1996) 73
55. Mitchell T.N. Organotin Reagents in Cross-Coupling Reactions. In: de Meijere A., and Diederich F. (Eds). Metal-Catalyzed Cross-Coupling Reactions Vol. 1 (2004), Wiley-VCH, Weinheim 125-161 Chapter 3
56. Stille J.K., and Simpson J.H. J. Am. Chem. Soc. 109 (1987) 2138
57. Shirakawa E., Morita R., Tsuchimoto T., and Kawakami Y. J. Am. Chem. Soc. 126 (2004) 13614
58. Markt P., Petersen R.K., Flindt E.N., Kristiansen K., Kirchmair J., Spitzer G., Distinto S., Schuster D., Wolber G., Laggner C., and Langer T. J. Med. Chem. 51 (2008) 6303
59. Itoh T., Fairall L., Amin K., Inaba Y., Szanto A., Balint B.L., Nagy L., Yamamoto K., and Schwabe J.W.R. Nat. Struct. Mol. Biol. 15 (2008) 924
60. Cronet P., Petersen J.F.W., Folmer R., Blomberg N., Sjöblom K., Karlsson U., Lindstedt E.-L., and Bamberg K. Structure 9 (2001) 699
61. Gampe Jr. R.T., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliewer S.A., Willson T.M., and Xu E. Mol. Cell. 5 (2000) 545
62. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Nature 395 (1998) 137
63. Pochetti G., Godio C., Mitro N., Caruso D., Galmozzi A., Scurati S., Loiodice F., Fracchiolla G., Tortorella P., Laghezza A., Lavecchia A., Novellino E., Mazza F., and Crestani M. J. Biol. Chem. 282 (2007) 17314
64. The first complete structure of a NR heterodimer, PPARγ-RXRα, including the DNA binding domain has recently been published:. Chandra V., Huang P., Hamuro Y., Raghuram S., Wang Y., Burris T.P., and Rastinejad F. Nature 456 (2008) 350
65. Pople, J. A. et al. gaussian 98, revision A.11.2; Gaussian: Pittsburgh, PA, 2001.
66. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639
67. AutoDock: Automated docking of flexible ligands to receptors, Version 3.0, The Scripps Research Institute, La Jolla, CA, 1999.
68. Goodford, P. J. Med. Chem. 1985, 28, 849-857. http://www.moldiscovery.com/.
69. To confirm that the selected protein-ligand complex is suitable for the docking problem we have done redocking of the crystal structure ligand to the protein and determined the good reproducibility of all important ligand-protein interactions of the crystal structure ligand (see S.I., Fig. 1).
70. Metrangolo P., Neukirch H., Pilati T., and Resnati G. Acc. Chem. Res. 38 (2005) 386
71. Auffinger P., Hays F.A., Westhof E., and Ho P.S. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 16789
72. Memic A., and Spaller M.R. ChemMedChem 9 (2008) 2793
73. 2 3 have recently been described, but their PPARγ transactivation potency is lower than that of compound 18, and no studies with the other PPAR paralogues were reported; see:. Iqbal M., Duffy P., Evans P., Cloughley G., Allan B., Lledó A., Verdaguer J., and Riera A. Org. Biomol. Chem. 6 (2008) 4649